South Finance Intelligence News, November 27th: Hengrui Pharma (stock code: 01276.HK) announced that recently, Jiangsu Hengrui Pharmaceutical Co., Ltd. and its subsidiaries Suzhou Shendiya Biopharmaceutical Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., and Shanghai Shendi Pharmaceutical Co., Ltd. have received the approval notice for clinical trials from the National Medical Products Administration regarding Injection HRS-7058 Capsule, HRS-7058 Tablets, SHR-9839(sc), Adabeleli Monoclonal Antibody Injection, Bevacizumab Injection, Injection SHR-A2102. These approvals allow for the conduct of clinical trials. Specifically, it is an II-phase clinical study of HRS-7058 combined with anti-tumor drugs in subjects with solid tumors. SHR-9839 is a company-developed humanized antibody drug, intended for the treatment of advanced solid tumors. As of now, the cumulative R&D investment for this project is approximately 72.31 million yuan. Adabeleli Monoclonal Antibody Injection is a company-developed humanized anti-PD-L1 monoclonal antibody. As of now, the cumulative R&D investment for this project is approximately 969 million yuan. Bevacizumab Injection is a company's marketed product. As of now, the cumulative R&D investment for this project is approximately 365 million yuan. Injection SHR-A2102 is a company-developed antibody-drug conjugate targeting Nectin-4. As of now, the cumulative R&D investment for this project is approximately 248 million yuan. HRS-7058 is a new type of small molecule covalent inhibitor, intended for the treatment of advanced solid tumors with KRASG12C mutations. As of now, the cumulative R&D investment for this formulation is approximately 63.91 million yuan.

https://finance.eastmoney.com/a/202511273576712483.html